Related Experiment Videos
p53 Gene therapy for lung cancer
Stephen G Swisher1, Jack A Roth
1Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 445, Houston 77030, USA. sswisher@mdanderson.org
Current Oncology Reports
|June 5, 2002
Summary
Gene therapy using the p53 gene (Ad-p53) showed tumor regression in lung cancer patients. Intratumoral delivery demonstrated localized effects and acceptable safety, warranting further investigation in phase III trials.
Area of Science:
- Oncology
- Gene Therapy
- Cancer Research
Background:
- The tumor suppressor p53 gene plays a crucial role in cancer development.
- Gene transfer strategies are being explored for cancer treatment.
- Preclinical models suggest p53 gene transfer can induce tumor regression.
Purpose of the Study:
- To evaluate the safety and efficacy of adenoviral-mediated transfer of wild-type p53 (Ad-p53) in lung cancer patients.
- To assess Ad-p53 as a monotherapy and in combination with chemotherapy or radiotherapy.
- To determine the locoregional effects of intratumoral Ad-p53 delivery.
Main Methods:
- Phase I and II clinical studies were conducted.
- Adenoviral-mediated transfer of wild-type p53 (Ad-p53) was administered intratumorally.
- Treatment was given alone or combined with chemotherapy or radiotherapy.
Main Results:
- Ad-p53 demonstrated acceptable toxicity profiles.
- Evidence of tumor regression was observed following intratumoral delivery.
- The primary clinical effects were locoregional, confined to the delivery area.
Conclusions:
- Intratumoral Ad-p53 delivery shows promise for localized lung cancer treatment.
- Further phase III studies are necessary to confirm Ad-p53's therapeutic role in non-small-cell lung cancer.
- Ad-p53 represents a potential novel therapeutic agent for lung cancer.